Need for Speed

Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors

Retrieved on: 
Monday, January 22, 2024
Need for Speed, Psoriatic arthritis, Patient, US FDA, RealTime, TNF, Joint, Rheumatology, Mechanism of action, HCP, Skin, Secukinumab, MOA, Physician, Pharmaceutical industry

However, recent years have witnessed a transformative shift in both the US and EU markets, as rheumatologists increasingly favor alternative mechanisms, notably IL-17 inhibitors.

Key Points: 
  • However, recent years have witnessed a transformative shift in both the US and EU markets, as rheumatologists increasingly favor alternative mechanisms, notably IL-17 inhibitors.
  • In contrast, within that timeframe, rheumatologists saw a preference for IL-17s more than double, indicating a noteworthy transformation in treatment preferences.
  • Over half of rheumatologists cite efficacy as their primary motive for favoring IL-17 inhibitors in PsA treatment, regularly underscoring the class’s success in treating both skin and joint manifestations.
  • As the treatment landscape for PsA undergoes dynamic changes, staying ahead of these shifting trends becomes essential for effective patient management and optimal treatment outcomes.

Consecutive Use of TNF-Inhibitors for the Treatment of Psoriatic Arthritis at Lowest Point Recorded, as Use of Biologics with Alternate Mechanisms of Actions Continue to Grow, According to Spherix Global Insights

Retrieved on: 
Tuesday, October 3, 2023
Ixekizumab, Secukinumab, Amgen, NASA RealWorld-InWorld Engineering Design Challenge, MOA, TNF, Arthritis, Upadacitinib, Eli Lilly and Company, Risankizumab, Rheumatology, Patient, Psoriatic arthritis, Novartis, AbbVie, Algorithm, Physician, Need for Speed, Kwaku Amoa-Awuah, Safety, Guselkumab, Pharmaceutical industry, Apremilast

This results in a substantial patient population, with each physician handling an average of forty or more patients who switch their treatment on an annual basis.

Key Points: 
  • This results in a substantial patient population, with each physician handling an average of forty or more patients who switch their treatment on an annual basis.
  • Spherix Global Insights recently published its seventh annual Patient Chart Dynamix™: Triggers and Drivers in Psoriatic Arthritis, (previously RealWorld Dynamix: Switching in Psoriatic Arthritis).
  • Patients receiving TNFs are also provided an ample period of treatment in the first-line setting before considering a switch to an alternative therapy.
  • Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits.

OKX and McLaren Racing Host Exclusive Panel on the Impact of Technology in Sports and Film at Tribeca Festival

Retrieved on: 
Wednesday, June 14, 2023
Crypto, Tribeca, Partnership, Web3, Formula One, Tribeca Festival, McLaren F1, F1, Shadow, Partner, Need for Speed, OKX, McLaren, Webby Awards, Film industry, Sport

During the discussion, the panelists emphasized the impact of innovation on speed, performance and efficiency across the different sectors.

Key Points: 
  • During the discussion, the panelists emphasized the impact of innovation on speed, performance and efficiency across the different sectors.
  • Our goal is to help McLaren transcend into this future and share what we are cooking together on our panel".
  • In May of last year, OKX and McLaren Racing announced a multi-year partnership that would make OKX a Primary Partner of the McLaren Formula 1 Team and McLaren Shadow esports team.
  • OKX branding is featured on the McLaren cars, the helmets of McLaren F1 drivers Lando Norris and Oscar Piastri, as well as the McLaren F1 and McLaren Shadow team kits.

OKX and McLaren Racing Host Exclusive Panel on the Impact of Technology in Sports and Film at Tribeca Festival

Retrieved on: 
Wednesday, June 14, 2023
Crypto, Tribeca, Partnership, Web3, Formula One, Tribeca Festival, McLaren F1, F1, Shadow, Partner, Need for Speed, OKX, McLaren, Webby Awards, Film industry, Sport

During the discussion, the panelists emphasized the impact of innovation on speed, performance and efficiency across the different sectors.

Key Points: 
  • During the discussion, the panelists emphasized the impact of innovation on speed, performance and efficiency across the different sectors.
  • Our goal is to help McLaren transcend into this future and share what we are cooking together on our panel".
  • In May of last year, OKX and McLaren Racing announced a multi-year partnership that would make OKX a Primary Partner of the McLaren Formula 1 Team and McLaren Shadow esports team.
  • OKX branding is featured on the McLaren cars, the helmets of McLaren F1 drivers Lando Norris and Oscar Piastri, as well as the McLaren F1 and McLaren Shadow team kits.

OKX Strengthens Partnership with Tribeca Festival in Second Consecutive Year as Event's Presenting Partner

Retrieved on: 
Wednesday, May 31, 2023
Crypto, BMCC Tribeca Performing Arts Center, Partnership, Web3, Marketing, Speech, Culture, Tribeca Festival, TriBeCa Productions, F1, Need for Speed, System, OKX, Festival, Rewrite, Growth, Rafiq, DEX, McLaren, Cryptocurrency, Entertainment, Sport

NEW YORK, May 31, 2023 /PRNewswire/ -- OKX , a global-leading Web3 technology company, and Tribeca Festival today announced details of OKX's second consecutive sponsorship of the Tribeca Festival.

Key Points: 
  • NEW YORK, May 31, 2023 /PRNewswire/ -- OKX , a global-leading Web3 technology company, and Tribeca Festival today announced details of OKX's second consecutive sponsorship of the Tribeca Festival.
  • For the duration of the Festival, OKX will be the official name sponsor of the BMCC Tribeca Performing Arts Center, which will be renamed "The OKX Theater at BMCC Tribeca Performing Arts Center."
  • Throughout the Festival, OKX will outline its view of how Web3 can empower creators, including through the use of its Tribeca Festival NFT pass and by providing attendees with access to a Games & Immersive Experience lounge.
  • Now in year two, our partnership with OKX showcases how Tribeca Festival is weaving technology into culture and the creator economy.

Over Three Years after Receiving a Complete Response Letter From the FDA, Takeda's Subcutaneous Formulation of Entyvio (Entyvio SC) is Poised to Enter a Rapidly Evolving UC Market, According to Spherix Global Insights

Retrieved on: 
Friday, May 5, 2023
Takeda Pharmaceutical Company, Pressure, Injection, NASA RealWorld-InWorld Engineering Design Challenge, Risankizumab, EU, IV, TNF, Face, Takeda, JAK, SC, Mirikizumab, Eli Lilly and Company, Janssen, Ulcerative colitis, Traction, Patient, AbbVie, Physician, Need for Speed, CRL, BMS, Biosimilar, FDA, RealTime, Pharmaceutical industry, IL-23, Vedolizumab, Pfizer, Upadacitinib, Ustekinumab, UC

EXTON, Pa., May 4, 2023 /PRNewswire/ -- In December 2019, Takeda Pharmaceutical Company ("Takeda") announced the receipt of a complete response letter (CRL) for the subcutaneous (SC) formulation of its successful ulcerative colitis (UC) treatment, Entyvio (vedolizumab). The intravenous (IV) formulation of Entyvio is the only non-TNF UC therapy which enjoys a substantial share of advanced treated patients, and the highest share of any single brand.

Key Points: 
  • EXTON, Pa., May 4, 2023 /PRNewswire/ -- In December 2019, Takeda Pharmaceutical Company ("Takeda") announced the receipt of a complete response letter (CRL) for the subcutaneous (SC) formulation of its successful ulcerative colitis (UC) treatment, Entyvio (vedolizumab).
  • The intravenous (IV) formulation of Entyvio is the only non-TNF UC therapy which enjoys a substantial share of advanced treated patients, and the highest share of any single brand.
  • In the race to capture second-line UC patients, Janssen's Stelara (approved for UC in 2019) is currently favored by physicians.
  • Spherix will be monitoring the potential Entyvio SC US launch and the evolving UC market through its RealTime Dynamix™ advisory service.

New Mixed-Reality AAA Racing Game, Celeros, Announced to Support Real-World Social and Environmental Impact Projects

Retrieved on: 
Thursday, April 27, 2023
Partnership, Gran Turismo, Speeder, Collision, Need for Speed, AAA, Investment, Wipeout (video game), Collision avoidance system, Physics, Video game, List of Star Wars air, aquatic, and ground vehicles

Centred in offering a AAA racing experience as well as creating real-world professional pathways, Celeros will deliver sustainable, real-world impact via a balanced economic model that relies on investments in real-world social and environmental causes.

Key Points: 
  • Centred in offering a AAA racing experience as well as creating real-world professional pathways, Celeros will deliver sustainable, real-world impact via a balanced economic model that relies on investments in real-world social and environmental causes.
  • With 3.24bn active gamers around the world, Play2Impact has the potential to drive real change.
  • Through an official partnership with Airspeeder, the world's first crewed racing eVTOL series, AirspeederXR will be the first race series to take part in Celeros.
  • It will deliver an epic multiplayer racing experience, augmented by real-world physics data from thousands of hours of flight time.

Wells Fargo to Participate in Nacha’s Smarter Faster Payments Conference

Retrieved on: 
Tuesday, April 11, 2023
Technology, Payments, Finance, Fintech, Banking, Electronic Commerce, Professional Services, Digital Cash Management, Digital Assets, Data Analytics, Wells Fargo, Internet, Java transaction service, Head, Innovation, CTP, Multimedia, ACH, Need for Speed, Commercial bank, DE, History, ACH Network, WFC, ATM, Digital, Conference, NYSE, News, Participation

Wells Fargo announced its participation today at Nacha’s Smarter Faster Payments conference in Las Vegas from April 16-19.

Key Points: 
  • Wells Fargo announced its participation today at Nacha’s Smarter Faster Payments conference in Las Vegas from April 16-19.
  • View the full release here: https://www.businesswire.com/news/home/20230411005648/en/
    Wells Fargo to Participate in Nacha’s Smarter Faster Payments Conference (Photo: Wells Fargo)
    Nacha is the organization that governs the ACH Network, which facilitates electronic, bank-to-bank money transfers processed for consumers, businesses, and federal, state and local governments.
  • Five speakers from Wells Fargo will appear on panels at the conference:
    John Hunter, head of Global Treasury Management Payments & Transaction Services, will appear on the Feed the Need For Speed!
  • News, insights and perspectives from Wells Fargo are also available at Wells Fargo Stories .

BMS' Zeposia and AbbVie's Skyrizi Shake Up First-Line Prescribing Patterns in the US Ulcerative Colitis and Crohn's Disease Markets, Spherix Reports

Retrieved on: 
Wednesday, November 30, 2022
MOA, Adalimumab, Need for Speed, Dermatology, Gastroenterology, TNF, Infliximab, AbbVie, Rheumatology, NASA RealWorld-InWorld Engineering Design Challenge, Ustekinumab, Patient, Neurology, BMS, IBD, Face, Janssen, Receptor modulator, Eli Lilly and Company, Ophthalmology, Ulcerative colitis, Mirikizumab, Vedolizumab, Inflammatory bowel disease, Crohn's disease, Pfizer, Nephrology, FDA, Pharmaceutical industry, Risankizumab, Upadacitinib, Ozanimod, UC, Takeda

EXTON, Pa., Nov. 30, 2022 /PRNewswire/ -- US gastroenterologists estimate that just under 60% of their ulcerative colitis (UC) and 55% of their Crohn's disease (CD) patients treated with a biologic or small molecule are on their first-line advanced systemic therapy. Over the past eighteen months, the US inflammatory bowel disease (IBD) market has become increasingly competitive with the market entry of BMS' Zeposia and AbbVie's Rinvoq for the treatment of UC and AbbVie's Skyrizi in CD, which have had material changes to new start IBD treatment patterns.

Key Points: 
  • Spherix Global Insights ("Spherix") has been tracking the newly initiated IBD patient segment for the past five years via their RealWorld Dynamix service .
  • When specifically examining UC new starts, Zeposia, a first-in-class S1P receptor modulator, has made substantial inroads as a pre-biologic option, capturing a sizeable portion of first-line patients.
  • Unsurprisingly, the most prominent driver behind Zeposia use is the brand's oral administration, followed by the perceived efficacy and unique MOA.
  • Crohn's disease new start patterns have also been altered by the newest CD market entrant, Skyrizi.

Orionis Biosciences Presents Preclinical Data on Interferon and IL-2 Targeted Cytokine Immunotherapies for Cancer

Retrieved on: 
Monday, November 14, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Interferon, Iota Orionis, Cytokine, KINE-FM, Engineering, Toxicity, Cancer, Need for Speed, Myelocyte, Tumor necrosis factor receptor 1, Immune system, IND, Disease, Protein, Therapy, Interleukin, ILS, Vaccine, Pharmaceutical industry

The data demonstrate potent anti-tumor activity across multiple classes of targeted cytokines.

Key Points: 
  • The data demonstrate potent anti-tumor activity across multiple classes of targeted cytokines.
  • Today we shared preclinical data that represent exciting progress for our proprietary A-Kine platform.
  • Orionis deep and diversified A-Kine pipeline comprises multiple cytokine classes, including re-engineered interferons (IFNs), interleukins (ILs) and tumor necrosis factors (TNFs).
  • Orionis Biosciences is a life sciences company pioneering technological innovations in genome-scale drug discovery to develop novel, highly specific and tunable therapeutics for cancer and beyond.